109 individuals test positive for UK variant of Covid in India

109 individuals test positive for UK variant of Covid in India

Overview

  • Post By : Kumar Jeetendra

  • Source: Reuters

  • Date: 14 Jan,2021

The number of those who have tested positive for the new UK variant of SARS-CoV-2 in the nation has climbed to 109, the Union Health Ministry said on January 14. “The whole number of men found infected with the new UK variant genome stands at 109 now,” the ministry said.

All these individuals are stored in single room isolation in designated healthcare centers by respective state governments, the ministry had said previously.

Their close contacts also have been put under quarantine. Comprehensive contact tracing has been initiated for co-travelers, family contacts, and many others. Genome sequencing on other specimens is happening, the ministry said.

The presence of the new UK variant has already been reported by several countries including Denmark, the Netherlands, Australia, Italy, Sweden, France, Spain, Switzerland, Germany, Canada, Japan, Lebanon, and Singapore.

In the past year, high serum suPAR levels also have been found to predict kidney and multiple organ failure in hospitalized patients with COVID-19.

“FSGS is a particularly insidious kidney disease. In many patients, it inexorably leads to kidney failure and we don’t have much to offer to stop it, and worse still, in most patients it recurs after a kidney transplant, leading to failure of the transplanted kidney,” said Stuart E. Dryer, Moores Professor of biology and biochemistry, with a joint appointment as a professor of biomedical sciences in the UH College of Medicine. Dryer is working to identify possible new therapeutic targets for chronic kidney disease, particularly focal segmental glomerulosclerosis, and his very first place to look is the suPAR protein.

Greater suPAR levels in blood induce oxidative stress in the glomeruli, the tiny filtering units inside the kidney, and discharge oxygen-free radicals that attack cell membranes and disrupt ion channels, causing a rise in calcium levels within the cell. In many conditions, higher suPAR levels have bad prognostic indications.

“Basically, if you’re sick and your serum suPAR levels are high, you’re in trouble,” said Dryer. To block the action of suPAR, he’s examining a drug that has already undergone clinical trials for unrelated conditions, such as Alzheimer’s disease. A $1.4 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases affirms his job.

Dryer’s other favourite target is an ion channel protein known as TRPC6 (Transient Receptor Potential Cation Channel Subfamily C Member 6). Excessive activation of TRIPC6 causes FSGS and suPAR greatlyg raises the action of TRPC6.

“My lab has demonstrated the suPAR and TRPC6 are connected to one another,” said Dryer. “If you add suPAR to cells, TRPC6 gets more active,” said Dryer. “Now we need to understand better how TRPC6 actually works in related kidney cells.”

About Author